Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Update

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 1,100,000 shares, a drop of 29.9% from the December 15th total of 1,570,000 shares. Currently, 6.3% of the company’s shares are sold short. Based on an average trading volume of 9,060,000 shares, the days-to-cover ratio is presently 0.1 days.

Insider Buying and Selling

In other news, Director Nancy A. Simonian sold 134,713 shares of Syros Pharmaceuticals stock in a transaction on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares of the company’s stock, valued at $11,088.90. The trade was a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.26% of the stock is owned by company insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

Large investors have recently modified their holdings of the stock. GSA Capital Partners LLP purchased a new position in Syros Pharmaceuticals in the 3rd quarter worth approximately $34,000. Acadian Asset Management LLC lifted its position in shares of Syros Pharmaceuticals by 101.5% during the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after purchasing an additional 17,416 shares in the last quarter. Finally, Exome Asset Management LLC boosted its stake in shares of Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after purchasing an additional 139,400 shares during the period. Institutional investors and hedge funds own 91.47% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SYRS. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. StockNews.com began coverage on shares of Syros Pharmaceuticals in a report on Thursday. They issued a “sell” rating on the stock. Finally, JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Price Performance

NASDAQ SYRS traded up $0.01 during mid-day trading on Friday, hitting $0.21. The company’s stock had a trading volume of 339,382 shares, compared to its average volume of 2,484,598. Syros Pharmaceuticals has a 52-week low of $0.18 and a 52-week high of $7.96. The stock’s fifty day simple moving average is $0.40 and its two-hundred day simple moving average is $2.20. The firm has a market capitalization of $5.69 million, a P/E ratio of -0.07 and a beta of 1.31.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the business posted ($1.35) EPS. On average, equities analysts forecast that Syros Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.